Australian Tennis star Maria Sharapova failed a medication test at the current year’s Australian Open, she reported Monday at a news meeting in Los Angeles. She said in press “I failed the test, and I assume full liability for it.”
She said she was sent to the test in a letter sent by the International Tennis Federation a couple of days back. On Dec. 22, she said, she got an email from the World Anti-Doping Agency that recorded denied things for the up and coming year, however conceded that she “didn’t take a gander at that rundown.”
Sharapova said she had legitimately taken the medication being referred to, meldonium, since 2006 to treat a variety of wellbeing issues. At that time, she said, she was “getting sick a lot,” with a magnesium deficiency, irregular EKGs and early signs of diabetes.
Sharapova’s legal counselor, John Haggerty, said he couldn’t remark on where Sharapova’s family specialist was based. “I’m not attempting to be shifty, but rather that is the guidelines that we need to play by,” Haggerty told different media.
Meldonium is not a FDA-affirmed substance in the United States, however its utilization is regular in Eastern Europe and previous Soviet nations for individuals with heart conditions. It is likewise available to be purchased on the web. WADA checked the impacts and utilization of meldonium before reporting in September that it would be announced a banned substance in 2016.
Sharapova, a 28-year-old winner of five Grand Slam tournaments, is No. 7 in the World Tennis Assn. singles rankings, but she has not played since losing in the quarterfinals of the Australian Open six weeks ago. Last week, she pulled out of the BNP Paribas Open, which begins this week at Indian Wells, saying she was “extremely disappointed” but needed to continue healing a left forearm injury.
Sharapova said, “I don’t know where the end of my career this way and really hope that there will be an opportunity for me.”